Grenoble university hospital
Grenoble, 38043, France
NCT Number: NCT02833675
Diagnosis of angioedema (AE) is difficult especially in emergency room. Two forms should be evoked: histaminic AE (allergic or not, which represent 95% of cases) and bradykinic AE (hereditary or acquired deficiency, with or without C1 Inhibitor) rarer but with more severe prognosis. The distinction is based on clinical features (spontaneous crisis duration, presence of concomitant hives, atopic history...). Sometimes it could be difficult to make the difference. Nowadays, there is no biological marker of the crisis. The search for biomarkers could improve the diagnostic and therapeutic management of AE. Previous work has identified targets: D-dimer, C4, and VE-cadherin. We wanted to know the sensitivity and specificity of these markers.
We conducted a prospective study evaluating the D-dimer assays, complement and VE-cadherin during an episode of AE. Three groups of patients were tested: bradykinic AE (peripheral or abdominal attacks), histaminic AE, and abdominal pain (non-bradykinic and non-histaminic etiology) at the time (day 0) and at distance from the crisis (D7).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Grenoble, 38043, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 7 DAYS
Time frame: 7 DAYS
Time frame: 7 DAYS
University Hospital, Grenoble
Other
Acronym: BIOBRAD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07611032
Angioedema, Cardiovascular Diseases
Yongzhou, Hunan, China
View Trial DetailsNCT05936567
Angioedema, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05578417
Angioedema, Angioedemas, Hereditary
Calgary, Alberta, Canada
View Trial DetailsNCT04444895
Angioedema, Cardiovascular Diseases
Birmingham, Alabama, United States
View Trial Details